Pandemic H5N1 vaccine - Tria Bioscience/Immune Design

Drug Profile

Pandemic H5N1 vaccine - Tria Bioscience/Immune Design

Latest Information Update: 14 Jul 2016

Price : $50

At a glance

  • Originator TRIA Bioscience
  • Developer Immune Design; TRIA Bioscience
  • Class Influenza A virus H5N1 vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Influenza A virus H5N1 subtype

Most Recent Events

  • 14 Jul 2016 Preclinical trials in Influenza-A virus H5N1 subtype (Prevention) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top